Relacorilant
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Relacorilant, sold under the brand name Lifyorli, is an anti-cancer medication used for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Relacorilant is a glucocorticoid receptor antagonist. It is taken by mouth. The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite. Relacorilant was approved for medical use in the United States in March 2026.
Relacorilant, sold under the brand name Lifyorli, is an anti-cancer medication used for the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Relacorilant is a glucocorticoid receptor antagonist. It is taken by mouth. The most common adverse reactions include decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite. Relacorilant was approved for medical use in the United States in March 2026.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1366784074 under CC BY-SA 4.0; modifications have been made.